- Home
- NU vs REGN Comparison
NU vs REGN Comparison
Compare NU & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NU | REGN |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | Brazil | United States |
| Employees | 10027 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8B | 73.2B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NU | REGN |
|---|---|---|
| Price | $12.76 | $603.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 25 |
| Target Price | $18.08 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 58.1M | 984.1K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $180.93 | $12.45 |
| Revenue Next Year | $21.24 | $10.13 |
| P/E Ratio | ★ $33.29 | $90.01 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $11.20 | $518.90 |
| 52 Week High | $18.98 | $821.11 |
Technical Indicators
Market Signals| Indicator | NU | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 37.91 |
| Support Level | $11.50 | $591.52 |
| Resistance Level | $13.30 | $618.01 |
| Average True Range (ATR) | 0.46 | 15.75 |
| MACD | 0.15 | 3.37 |
| Stochastic Oscillator | 66.52 | 37.36 |
Price Performance
Historical ComparisonAbout NU Nu Holdings Ltd.
Nu Holdings Ltd is a Brazilian financial technology firm that offers digital banking services. Its services include Retail credit, SME credit, Payments, Customer assets, Insurance brokerage, E-commerce marketplace, and Mobile virtual network operator. It operates in single operating segment and geographically it operates in Brazil, Mexico, and Other countries with the majority of revenue deriving from Brazil.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.